Zusammenfassung
Die interindividuelle Ansprechbarkeit auf eine neuroleptische Therapie unterliegt einer beträchtlichen Variation. Im Prinzip kommen dafür 3 Hauptursachen in Betracht: 1. pharmakokinetische Unterschiede, die zu deutlich verschiedenen Neuroleptikakonzentrationen bei Patienten führen, die mit gleicher Dosierung behandelt werden; 2. unterschiedliche Dosis-Wirkungs-Beziehungen auf Rezeptorebene, die auf genetische oder andere krankheitsbezogene Faktoren zurückgeführt werden können; 3. Unterschiede in der Patientencompliance.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Aaes-Jorgensen T, Kirk L, Petersen E, Danneskiold-Samsoe P, Jorgensen A (1983) Serum con-centrations of the isomers of clopenthixol and a metabolite in patients given cis(Z)-clopenthixol decanoate in viscoleo. Psychopharmacology 81: 68–72
Amdur MA (1979) Medication compliance in outpatient psychotherapy. Compr Psychiatry 20: 339–346
Aravagiri M, Hawes EM, Midha KK (1984) Radioimmunoassay for the sulfoxide metabolite of trifluoperazine and its application to a kinetic study in humans. J Pharm Sci 73: 1383–1387
Benitez J, Pinjas B, Garcia MA, Martinez C, Llerena A, Cobaleda J (1989) Debrisoquine oxidation phenotype in psychiatric patients. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. From molecular studies to clinical reality. Springer, Berlin Heidelberg New York London Paris Tokyo Hongkong (Pharmacology series, vol 7 ), pp 206–216
Bressolle F, Bres J, Blanchin MD, Gomeni R (1984) Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. J Pharm Sci 73: 1128–1136
Dahl SG (1976) Pharmacokinetics of methotrimeprazine after single and multiple doses. Clin Pharmacol Ther 19: 435–442
Dahl SG (1981) Pharmacokinetic aspects of new antipsychotic drugs. Neuropharmacology 20: 1299–1302
Dahl SG (1986) Plasma level monitoring of antipsychotic drugs clinical utility. Clin Pharmacokinet 11: 36–61
Dahl SG, Strandjord RE (1977) Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21: 437–448
Dahl SG, Strandjord RE, Sigfusson S (1977) Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup. Eur J Clin Pharmacol 11: 305–310
Dahl SG, Johnsen H, Lee CR (1982 a) Gas chromatographic mass spectrometric identification of O-demethylated and monohydroxylated metabolites of levomepromazine in blood from psychiatric patients by selected ion recording with high resolution. Biomed Mass Spectrom 9: 534–538
Dahl SG, Bratlid T, Lingjaerde O (1982 b) Plasma and erythrocyte levels of methotrimeprazine and two of its nonpolar metabolites in psychiatric patients. Ther Drug Monit 4: 81–87
Dahl SG, Kauffmann E, Mompon B, Purcell T (1987) Nuclear magnetic resonance analysis of methotrimeprazine (levomepromazine) hydroxylation in humans. J Pharm Sci 76: 541–544
Farde L, Wiesel F-A, Nilsson L, Sedvall G (1989) The potential of positron emission tomography for pharmacokinetic and pharmacodynamic studies of neuroleptics. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. From molecular studies to clinical reality. Springer, Berlin Heidelberg New York London Paris Tokyo Hong Kong (Psychopharmacology series, vol 7 ), pp 32–39
Gravem A, Engstrand E, Guleng RJ (1978) Cis(z)-clopenthixol and clopenthixol ( Sordinol) in chronic psychotic patients. Acta Psychiatr Scand 58: 384–388
Hals P-A, Hall H, Dahl SG (1986) Phenothiazine drug metabolites: Dopamine D2 receptor, α1- and α2-adrenoceptor binding. Eur J Pharmacol 125: 373–381
Hals P-A, Hall H, Dahl SG (1988) Muscarinic cholinergic and histamine HI reeptor binding of phenothiazine drug metabolites. Life Sci 43: 405–412
Hulka BS, Cassel JC, Kupper LL (1976) Disparities between medications prescribed and consumed among chronic disease patients. In: Lasagna L (ed) Patient compliance. Futura, Mount Kisco, NY, pp 123–152
Johnsen H, Dahl SG (1982) Identification of O-demethylated and ring-hydroxylated metabolites of methotrimeprazine (levomepromazine) in man. Drug Metab Dispos 10: 63–67
Jorgensen A (1980) Pharmacokinetic studies in volunteers of intravenous and oral cis(Z)- flupentixol and intramuscular cis(Z)-flupentixol decanoate in viscoleo. Eur J Clin Pharmacol 18: 355–360
Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridges JW, Chasseaud LF (eds) Progress in drug metabolism, vol 9. Taylor & Francis, London, pp 111–174
Jorgensen A, Aaes-Jorgensen T (1988) Pharmacokinetic variations of zuclopenthixol and flupentixol administered orally or intramuscularly as retard or depot formulations. Nord Psychiatr Tidsskr 42: 501–502
Jorgensen A, Aaes-Jorgensen T, Gravem A, Amtor KF, Dencker SJ, Rosell I, Baastrup PC, Buckhave J, Gram LF (1985) Zuclopenthixol decanoate in schizophrenia: serum levels and clinical state. Psychopharmacology 87: 364–367
Larsson M, Axelsson R, Forsman A (1984) On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoate. Curr Ther Res 36: 1071–1088
Marder S, Hawes EM, Putten T van, Hubbard JW, McKay G, Mintz J, May PRA, Midha KK (1986) Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate. Psychopharmacology 88: 480–483
Märtensson E, Nyberg G (1989) Active metabolites in plasma and CSF - Implications for therapeutic drug monitoring. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. From molecular studies to clinical reality. Springer, Berlin Heidelberg New York London Paris Tokyo Hong Kong (Psychopharmacology series, vol 7 ), pp 257–268
Mendlewicz J, Linkowski P, Alexandre J, Schoutens A (1981) Haloperidol plasma levels and clinical response in schizophrenia. In: Usdin E, Dahl SG, Gram LF, Lingjaerde O (eds) Clinical pharmacology in psychiatry -Neuroleptic and antidepressant research. Macmillan, London, pp 233–237
Morel E, Lloyd KG, Dahl SG (1987) Anti-apomorphine effects of phenothiazine drug metabolites. Psychopharmacology 92: 68–72
Petersen PV, Moller Nielsen I, Pedersen V, Jorgensen A, Lassen N (1977) Thioxanthenes. In: Usdin E, Forrest IS (eds) Psychotherapeutic drugs, part 2: Applications. Dekker, New York, pp 827–867
Putten T van, May PRA, Jenden DJ (1981) Does a plasma level of chlorpromazine help? Psychol Med 11: 729–734
Usdin E (1971) The assay of chlorpromazine and metabolites in blood, urine and other tissues. CRC Grit Rev Clin Lab Sci 2: 347–391
Weiner PK, Langridge RL, Blaney JM, Schaefer R, Kollman PA (1982) Electrostatic potential molecular surfaces. Proc Natl Acad Sci USA 79: 3754–3758
Wiesel F-A, Alfredsson G, Ehrnebo M, Sedvall G (1980) The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. Eur J Clin Pharmacol 17: 385–391
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Dahl, S.G. (1990). Pharmakokinetik der Neuroleptika. In: Müller-Oerlinghausen, B., Möller, HJ., Rüther, E. (eds) Thioxanthene. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75194-3_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-75194-3_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-51847-1
Online ISBN: 978-3-642-75194-3
eBook Packages: Springer Book Archive